 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2026, vol. 32, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2026321.6732
Published online: 20 February 2026
Original article
J of IMAB. 2026 Jan-Mar;32(1):6732-6740
TREATMENT EFFECTS ON THE ROS PRODUCTION, LIPID PEROXIDATION AND OXIDATIVE DAMAGES IN IBD PEDIATRIC PATIENTS
Marlena Panayotova1
, Mariana Penkova2,
1) Department of Pediatrics – Trakia University Hospital, Stara Zagora; Trakia University – Stara Zagora, Bulgaria.
2) Department of Gastroenterology, University Hospital "Prof. St. Kirkovich", Stara Zagora; Trakia University – Stara Zagora, Bulgaria.
ABSTRACT:
Background: Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder encompassing Crohn’s disease (CD) and ulcerative colitis (UC). Increasing evidence suggests that impaired intestinal immune regulation in IBD is closely linked to an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, resulting in oxidative stress. Excessive ROS generation and lipid peroxidation contribute to mucosal injury, activation of inflammatory signaling pathways, and disease progression.
Objective: The aim of this study was to evaluate the role of oxidative stress markers—ROS production and malondialdehyde (MDA)—measured in peripheral blood, as well as antioxidant status, in relation to disease course and treatment in patients with IBD.
Materials and Methods: A cross-sectional study was conducted including 21 children and young adults with IBD (aged 14–25 years; mean age ~17.1 years) and 22 age-matched healthy controls (mean age ~17.6 years). Among the IBD cohort, 9 patients (42%) were male and 12 (58%) were female; 7 patients were diagnosed with CD and 14 with UC. All IBD patients underwent histological assessment.
Results: Increased ROS production was positively correlated with elevated MDA levels, indicating enhanced lipid peroxidation and oxidative stress in patients with IBD.
Conclusions: The therapeutic efficacy of anti-inflammatory treatments, including azathioprine, corticosteroids, mesalazine, and biological agents, may be partly attributed to their capacity to reduce ROS production and lipid peroxidation in intestinal mucosal cells, thereby promoting mucosal healing in patients with IBD.
Keywords: IBD, ROS production, lipid peroxidation, anti-inflammatory drug efficacy,
- Download FULL TEXT /PDF 1401 KB/
Please cite this article as: Panayotova M, Penkova M. Treatment Effects on the ROS Production, Lipid Peroxidation and Oxidative Damages in IBD Pediatric Patients. J of IMAB. 2026 Jan-Mar;32(1):6732-6740. [Crossref - 10.5272/jimab.2026321.6732]
Correspondence to: Marlena PanayotovaqDepartment of Pediatrics, Trakia Hospital; 1, Dunav Str., 6000 Stara Zagora, Bulgaria; E-mail: marlena.panayotova@trakia-uni.bg
REFERENCES:
1. Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol. 2022 Jan;15(1):10-26. [PubMed ]
2. Abdel Hadi L, Di Vito C, Riboni L. Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces. Mediators Inflamm. 2016;2016:3827684. [PubMed]
3. Aviello G, Knaus UG. NADPH oxidases and ROS signaling in the gastrointestinal tract. Mucosal Immunol. 2018; 11:1011–23. [PubMed]
4. Xu J, Chu T, Yu T, Li N, Wang C, Li C, et al. Design of diselenide-bridged hyaluronic acid nano-antioxidant for efficient ROS scavenging to relieve colitis. ACS Nano. 2022; 16:13037-48. [Crossref]
5. Jakubczyk K, Dec K, Kałduńska J, Kawczuga D, Kochman J, Janda K. Reactive oxygen species - sources, functions, oxidative damage. Pol Merkur Lekarski. 2020; 48:124-7. [PubMed]
7. Luceri C, Bigagli E, Agostiniani S, Giudici F, Zambonin D, Scaringi S, et al. Analysis of oxidative stress-related markers in crohn's disease patients at surgery and correlations with clinical findings. Antioxidants. 2019; 8:378. [PubMed]
8. Barrera G, Pizzimenti S, Daga M, Dianzani C, Arcaro A, Cetrangolo GP, et al. Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders. Antioxidants. 2018; 7:102. [PubMed]
9. Gęgotek A, Skrzydlewska E. Biological effect of protein modifications by lipid peroxidation products. Chem Phys Lipids. 2019; 221:46–52. [PubMed]
10. Miller CJ, Rose AL, Waite TD. Hydroxyl radical production by H2O2 -mediated oxidation of fe(II) complexed by suwannee river fulvic acid under circumneutral freshwater conditions. Environ Sci Technol. 2013; 47:829–35. [PubMed]
11. Baschieri A, Jin Z, Amorati R. Hydroperoxyl radical (HOO•) as a reducing agent: unexpected synergy with antioxidants. A review. Free Radic Res. 2023; 57:115–29. [PubMed]
12. Sanders LM, Henderson CE, Hong MY, Barhoumi R, Burghardt RC, Carroll RJ, et al. Pro-oxidant environment of the colon compared to the small intestine may contribute to greater cancer susceptibility. Cancer Lett. 2004; 208:155–61. [PubMed]
13. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1:514. [PubMed]
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. British Med Journal. 1989; 298:82-6. [PubMed]
15. Buckell NA, Lennard-Jones JE, Hernandez MA, Kohn J, Riches PG, Wadsworth J. Measurements of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut. 1979;20: 22–7. [PubMed]
16. Shi H, Sui Y, Wang X, Luo Y, Ji L. Hydroxyl radical production and oxidative damage induced by cadmium and naphthalene in liver of Carassius auratus. Comp. Biochem. Phys. Part C Toxicol. Pharmacol. 2005; 140, 115–121. [PubMed]
17. Perrone S, Santacroce A, Longini M, Proietti F, Bazzini F, Buonocore, G. The free radical diseases of prematurity: From cellular mechanisms to bedside. Oxidative Med Cell Longev. 2018; 7483062. [PubMed]
18. Takeshita K, Saito K, Ueda JI, Anzai K, Ozawa T. Kinetic study on ESR signal decay of nitroxyl radicals, potent redox probes for in vivo ESR spectroscopy, caused by reactive oxygen species. Biochim Biophys Acta. 2002 Nov 14;1573(2):156-64. [PubMed]
19. Xu S, Li X, Zhang S, Qi C, Zhang Z, Ma R, et al. Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian randomization study. BMC Med. 2023; 21:179. [PubMed]
20. Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F, et al. The emerging role of oxidative stress in inflammatory bowel disease. Front Endocrinol (Lausanne). 2024 Jul 15;15:1390351. [PubMed]
21. Tüzün A, Erdil A, İnal V, Aydın A, Bağcı S, Yeşilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin biochem. 2002; 35(7): 569-572. [PubMed]
22. Durak I, Yasa MH, Bektas A, Kacmaz M, Cimen MY, Ozturk HS. Mucosal antioxidant defense is not impaired in ulcerative colitis. Hepatogastroenterol. 2000; 47:1015–7. [PubMed]
23. Tavassolifar MJ, Changaei M, Salehi Z, Ghasemi F, Javidan M, Nicknam MH, Pourmand MR. Redox imbalance in Crohn's disease patients is modulated by azathioprine. Red Report. 2021; 26(1), 80-84. [PubMed]
24. Thomas AG, Miller V, Shenkin A, Fell GS, Taylor F. Selenium and glutathione peroxidase status in paediatric health and gastrointestinal disease. J Pediatr Gastroenterol Nutr 1994; 19:213–219. [PubMed]
25. Dudzińska E, Gryzinska M, Ognik K, Gil-Kulik P, Kocki J, Oxidative stress and effect of treatment on the oxidation product decomposition processes in IBD. Oxid Med Cell Longevity. 2018; 7918261. [PubMed]
26. Wan X, Zhang C, Lei P, Wang H, Chen R, Yang Q, Cheng Y, Wu W, Sun D, Hong X, Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery. J Materials Chem. 2025; 13(10):3245-3269. [PubMed]
27. Georgieva E, Ananiev J, Yovchev Y, Arabadzhiev G, Abrashev H, Zaharieva V, et al. Stable Nitroxide as Diagnostic Tools for Monitoring of Oxidative Stress and Hypoalbuminemia in the Context of COVID-19. Int J Mol Sci. 2024 24 Jul.;25(15):8045. [PubMed]
28. Petit C, Rozières A, Boschetti G, Viret C, Faure M, Nancey S, et al. Advances in Understanding Intestinal Homeostasis: Lessons from Inflammatory Bowel Disease and Monogenic Intestinal Disorder Pathogenesis. Intern J Mol Sci. 2025; 26(13), 6133. [PubMed]
29. Velayutham M, Kupec J, Khramtsov V and Rajendran V. Electron Paramagnetic Resonance (EPR) Spectroscopy to Measure Oxidative Stress (OS) in Ulcerative Colitis Mouse. Physiol. 2024; 39(S1), 1018.
30. Wang KY, Heikal OS, van Rheenen PF, Touw DJ, Bourgonje AR, Mian P. Clinical and Biochemical Factors Associated with Infliximab Pharmacokinetics in Paediatric Patients with Inflammatory Bowel Disease. J Clin Med. 2025; 14(3):845. [Pubmed]
31. Bourgonje AR, Gabriëls RY, de Borst MH, Bulthuis MLC, Faber KN, van Goor H. Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease. Antioxidants. 2019; 8:351. [PubMed]
32. Neubauer K, Kempinski R, Matusiewicz M, Bednarz-Misa I, Krzystek-Korpacka M. Nonenzymatic serum antioxidant capacity in IBD and its association with the severity of bowel inflammation and corticosteroids treatment. Med (B. Aires). 2019; 55:88. [PubMed]
33. Bohra A, Batt N, Dutt K, Sluka P, Niewiadomski O, Vasudevan A, et al. Prospective Evaluation of Serum Free Thiols in Inflammatory Bowel Disease: A Candidate to Replace C-Reactive Protein for Disease Activity Assessment? Inflamm Bowel Dis. 2025 Feb 6;31(2):476-484. [PubMed]
Received: 05 August 2025
Published online: 20 February 2026